Annals of Hematology

, Volume 98, Issue 3, pp 615–623 | Cite as

The impact of chronic myeloid leukemia on employment: the French prospective study

  • Sandra De Barros
  • Flora Vayr
  • Fabien Despas
  • Mathilde Strumia
  • Clémentine Podevin
  • Martin Gauthier
  • Eric Delabesse
  • Jean-Marc Soulat
  • Guy Laurent
  • Françoise Huguet
  • Fabrice HerinEmail author
Original Article


Patients with chronic myeloid leukemia treated with breakpoint cluster region-Abelson tyrosine kinase inhibitors are likely to survive in excess of 20 years after diagnosis. New challenges appear as we consider life after the disease, including professional challenges and the social reintegration of patients. The purpose of this study was to determine the impact of chronic myeloid leukemia on employment within 2 years after diagnosis. This prospective, observational study included patients diagnosed with chronic myeloid leukemia and treated with a tyrosine kinase inhibitor. Two populations were defined as patients who reported modifications in their professional activity during the study (Acti-Pro+) and patients who did not report a modification (Acti-Pro−). Cancer survivors received a self-assessment questionnaire. The primary endpoint was to determine the professional status of patients. One hundred patients completed the questionnaire. Sixty-six patients out of 100 reported professional activity within 2 years after their diagnosis. During the 2 years after the diagnosis, 65.2% (95% confidence interval (CI), 53.7–76.7) of patients faced modifications in their professional activity due to chronic myeloid leukemia or adverse effects of drug treatments (group Acti-Pro+); in contrast, 34.8% of patients did not report any impact on their occupational activity (group Acti-Pro−). Among modifications to work organization, a change in the number of working hours was the most represented. Other modifications comprised changes in status or work pace. A majority of chronic myeloid leukemia patients face professional consequences of their disease and treatments. Our findings suggest that adverse drug reactions are a major factor affecting the occurrence of work modifications in this context.


Cancer Chronic myeloid leukemia Return to work Occupational health practice 


Authors’ contributions

SDB, FV, FD, FHu, and FHe created the study concept and design. CP, MG, MS, and FD performed the acquisition of data. SDB, FV, FHu, FD, JMS, ED, GL, and FHe performed the analysis and interpretation of data. SDB, FV, FHu, and FHe wrote the draft of the manuscript. FD, ED, JMS, GL, and FHu undertook critical revision of the manuscript. All authors read and approved the final manuscript.


This work received support from the National Research Agency (Agence Nationale de la Recherche (ANR)) for “investissement d’avenir” (“Investment in the Future”) (ANR-11-PHUC-001; CAPTOR). The financial support was used to perform the data collection. The ANR was not involved in the design of the study, analysis, interpretation of data, or writing the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval and consent to participate

All procedures performed in the study that involved human participants were in accordance with the ethical standards of the institutional committee, national research committee, and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Availability of data and material

The datasets generated and analyzed during the study are available from the corresponding author on reasonable request.

Supplementary material

277_2018_3549_MOESM1_ESM.pdf (134 kb)
ESM 1 (PDF 134 kb)
277_2018_3549_MOESM2_ESM.pdf (52 kb)
ESM 2 (PDF 51 kb)


  1. 1.
    Estimation nationale de l’incidence des cancers en France entre 1980 et 2012 (2013) Maladies chroniques et traumatismes/Rapports et synthèses/Publications et outils/Accueil [Internet]. Disponible sur: Accessed 24 Nov 2017
  2. 2.
    Repsold L, Pool R, Karodia M, Tintinger G, Joubert AM (2017) An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia. Cancer Cell Int 17:89 Disponible sur: CrossRefGoogle Scholar
  3. 3.
    Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional... - Abstract - Europe PMC [Internet]. Disponible sur: Accessed 24 Nov 2017
  4. 4.
    Breccia M, Efficace F (2016) Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough? Current Med Res Opin 32(8):1453–1454CrossRefGoogle Scholar
  5. 5.
    Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HSL, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB (2013) Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 21(4):1097–1103CrossRefGoogle Scholar
  6. 6.
    Horsboel TA, Nielsen CV, Nielsen B, Jensen C, Andersen NT, de Thurah A (2013) Type of hematological malignancy is crucial for the return to work prognosis: a register-based cohort study. J Cancer Surviv 7(4):614–623CrossRefGoogle Scholar
  7. 7.
    Hamerschlak N, de Souza C, Cornacchioni AL, Pasquini R, Tabak D, Spector N, Steagall M (2014) Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor. Support Care Cancer 22(8):2113–2118Google Scholar
  8. 8.
    Horsboel TA, Nielsen CV, Nielsen B, Andersen NT, De Thurah A (2015) Wage-subsidised employment as a result of permanently reduced work capacity in a nationwide cohort of patients diagnosed with haematological malignancies. Acta Oncol 54(5):743–749CrossRefGoogle Scholar
  9. 9.
    Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884CrossRefGoogle Scholar
  10. 10.
    Common Terminology Criteria for Adverse Events (CTCAE)|Common Terminology Criteria for Adverse Events (CTCAE)|Protocol Development|CTEP [Internet]. Available from: Accessed 14 Jun 2018
  11. 11.
    Chow SL, Ting AS, Su TT (2014) Development of conceptual framework to understand factors associated with return to work among cancer survivors: a systematic review. Iran J Public Health 43(4):391–405Google Scholar
  12. 12.
    Nachreiner NM, Dagher RK, McGovern PM, Baker BA, Alexander BH, Gerberich SG (2007) Successful return to work for cancer survivors. AAOHN J 55(7):290–295CrossRefGoogle Scholar
  13. 13.
    Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C et al (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV. Blood 118(26):6760–6768CrossRefGoogle Scholar
  14. 14.
    Efficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F, Iurlo A, Russo Rossi A, Luciano L, Martino B, Galimberti S, Turri D, Bergamaschi M, Tiribelli M, Fava C, Angelucci E, Mandelli F, Baccarani M (2016) The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Ann Hematol 95(2):211–219CrossRefGoogle Scholar
  15. 15.
    Unnikrishnan R, Veeraiah S, Ganesan P (2017) Symptom burden and quality of life issues among patients of chronic myeloid leukemia on long-term imatinib therapy. Indian J Med Paediatr Oncol 38(2):165–168Google Scholar
  16. 16.
    Flynn KE, Atallah E (2016) Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep 11(2):80–85CrossRefGoogle Scholar
  17. 17.
    Kekäle M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 9:1733–1740CrossRefGoogle Scholar
  18. 18.
    Saiki CB, Waldfogel JM, Lee EK, Smith TJ (2017) Strategies for addressing cancer patients’ complaints of fatigue. Oncology (Williston Park, NY) 31(11):808–812Google Scholar
  19. 19.
    Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F (2013) Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 27(7):1511–1519CrossRefGoogle Scholar
  20. 20.
    Seifart U, Schmielau J (2017) Return to work of cancer survivors. Oncol Res Treat 40(12):760–763CrossRefGoogle Scholar
  21. 21.
    Schmielau J, Rick O, Reuss-Borst M, Kalusche-Bontemps E-M, Steimann M (2017) Rehabilitation of cancer survivors with long-term toxicities. Oncol Res Treat 40(12):764–771CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Sandra De Barros
    • 1
  • Flora Vayr
    • 2
  • Fabien Despas
    • 1
    • 3
    • 4
  • Mathilde Strumia
    • 1
  • Clémentine Podevin
    • 1
  • Martin Gauthier
    • 5
  • Eric Delabesse
    • 6
  • Jean-Marc Soulat
    • 2
    • 4
  • Guy Laurent
    • 4
    • 5
  • Françoise Huguet
    • 5
  • Fabrice Herin
    • 2
    • 4
    Email author
  1. 1.Department of Clinical PharmacologyToulouse University HospitalToulouseFrance
  2. 2.Department of Occupational DiseasesToulouse University HospitalToulouse Cedex 9France
  3. 3.Laboratory of Clinical PharmacologyUniversité Toulouse IIIToulouseFrance
  4. 4.INSERM UMR1027 (The French National Institute of Health and Medical Research)Université Toulouse IIIToulouseFrance
  5. 5.Department of HematologyToulouse University Hospital, IUCT-OToulouseFrance
  6. 6.Hematology LaboratoryToulouse University HospitalToulouseFrance

Personalised recommendations